Weekly Spotlight - 21.11.24

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

Latest News

New Medication Approved for Adults with Primary Immunoglobulin A Nephropathy

The UK has approved a new drug called sparsentan to treat adult patients with IgA nephropathy, a kidney disease. This medication aims to slow down the progression of the disease and reduce proteinuria, a common symptom of IgA nephropathy. It offers a new treatment option for those affected by this condition.

Everest Medicines' Nefecon Gains Full Approval in South Korea for Treating Primary IgA Nephropathy

Everest Medicines announced that Nefecon, a new medication, has been fully approved by South Korea's Ministry of Food and Drug Safety for the treatment of primary iga nephropathy, offering a new therapeutic option for patients with this condition.

UK's MHRA Approves Filspari for Rare Kidney Disease Treatment

The UK's MHRA has approved Filspari, a new treatment for IgA nephropathy, a kidney disease. Filspari is designed to reduce proteinuria and slow the progression of the disease. This approval offers a new therapeutic option for patients suffering from IgA nephropathy, potentially improving their quality of life.

New Treatments on the Horizon for IGA Nephropathy Patients

The article discusses new and experimental treatments for iga nephropathy, a kidney disease. It highlights various therapies, including medications and lifestyle changes, that are being researched to improve outcomes for patients with this condition. The focus is on potential future treatments that could offer better management and prevention of kidney damage.